Iluvien

Partner Perspective: Patient Case Study - CONTINUOUS MICRODOSING™ TREATMENT WITH ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg
New paradigm shift in selecting a steroid course prior to FAc implantAs retinal specialists, we are truly fortunate to live in a time where we have several treatment options for patients with diabetic macular edema (DME). A fluocinolone acetonide (FAc) intravitreal implant 0.19 mg (Iluvien, Alimera Sciences) is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP.
Latest concepts in steroid therapy for diabetic macular oedemaSteroids are an important second-line treatment for the treatment of diabetic macular oedema. While side effects remain a concern, modern formulations of intravitreal steroid allow the treatment to be tailored to the individual patient.
Real-world experience: Positive DME treatment outcomes observed with FAc implant at UK centreDr Mushtaq discusses one centre’s initial post-marketing experience with the fluocinolone acetonide intravitreal implant 0.19 mg. The implant demonstrated favourable outcomes and good patient acceptance.
Real-world experience: Case study shows maintained benefits with FAc in DME patientIn the case study discussed in this article, a patient who was treated for DME with a fluocinolone acetonide intravitreal implant reported improved vision-related quality of life and the ability to perform daily routines without problems. These benefits persisted 12-months after treatment.
First long-term treatment for DME approved by FDAFDA has approved fluocinolone acetonide intravitreal implant (Iluvien, Alimera) 0.19 mg for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). Iluvien was approved without any restriction requiring patients to have undergone, or be scheduled for, cataract surgery.
FDA approves Iluvien for long-term treatment of DME; Alimera reactsThe FDA has approved Alimera Sciences’ fluocinolone acetonide intravitreal implant (Iluvien) for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP.
Iluvien receives national marketing authorization in 10th countryThe Swedish Medical Products Agency has granted marketing authorization of Alimera Sciences’ Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
Iluvien for chronic DME approved for marketing in Denmark, NorwayThe Danish Health and Medicines Authority, along with the Norwegian Medicines Evaluation Board, have granted marketing authorization to Alimera Sciences’ Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema (DME) in their respective countries.
Iluvien receives positive approval from 10 more countriesAlimera Sciences' sustained-release intravitreal implant (Iluvien)—its treatment of chronic macular edema—has received a positive outcome of the Repeat-Use Procedure with the Medicines and Healthcare products Regulatory Agency of the United Kingdom serving as the Reference Member State.